Antitumor effect of L-alanosine (NSC 153553) on sensitive and resistant sublines of murine leukemias.
The antitumor action of L-alanosine (NSC 153553) was investigated in murine leukemia P388 (P388/S), P388 resistant to adriamycin (P388/ADR), P388 resistant to vincristine (P388/VCR) and leukemia L5178Y sensitive to L-asparaginase (L5178Y/S). L-alanosine demonstrated good antineoplastic activity against P388/S and P388/ADR, whereas it showed better anticancer activity against P388/VCR and L5178Y/S at the various dose levels employed.
D000409:Alanine / Q000031:analogs & derivatives / Q000627:therapeutic use; D000818:Animals; D001215:Asparaginase / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D004351:Drug Resistance; D007942:Leukemia, Experimental / Q000188:drug therapy*; D008297:Male; D051379:Mice; D014750:Vincristine / Q000627:therapeutic use
C000082:alanosine; D014750:Vincristine; D004317:Doxorubicin; D001215:Asparaginase; D000409:Alanine